Topiramate
Product Images NDC 70934-748

4 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-748). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (70934 748 90 Master Bottle Label Approval Rev A 05 20)

Label (70934 748 90 Master Bottle Label Approval Rev A 05 20)
Topiramate Tablets USP 25 mg label from Denton Pharma, Inc. dba Northwind Pharmaceuticals. The label indicates a package of 90 tablets, prescription only. Storage instructions specify controlled room temperature (20°-25°C). Additional handling and dosage instructions are referenced.*
FDA Label Image

A9eed983 Edf1 4f44 A8ec 568a52f03015 01

A9eed983 Edf1 4f44 A8ec 568a52f03015 01
Chemical structure of topiramate showing its molecular framework with oxygen, sulfur, nitrogen atoms, and methyl groups including sulfate and bicyclic features.*
FDA Label Image

A9eed983 Edf1 4f44 A8ec 568a52f03015 02

A9eed983 Edf1 4f44 A8ec 568a52f03015 02
A Kaplan-Meier survival curve chart showing cumulative rates over time to first seizure for two dosages of topiramate: 50 mg/day and 400 mg/day. The x-axis represents time in days up to 500 days, and the y-axis represents cumulative rates from 0 to 0.5. The solid line corresponds to 50 mg/day (N=234) and the dashed line to 400 mg/day (N=236), with a P-value of 0.0002 noted.*
FDA Label Image

A9eed983 Edf1 4f44 A8ec 568a52f03015 03

A9eed983 Edf1 4f44 A8ec 568a52f03015 03
A bar graph showing the change from baseline to double-blind phase in average monthly migraine period rate with topiramate doses of 50 mg/day, 100 mg/day, and 200 mg/day compared to placebo. The graph includes data from two studies (Study 10 and Study 11), with overall reductions in migraine period rates increasing with higher doses of topiramate. Statistical significance is indicated for doses 100 mg/day and 200 mg/day.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.